|
|
| |
|
|
Symposium on Recent Advancements on Drug Discovery Science and Technology |
|
| |
|
Symposium on Novel Drug Delivery Systems and Technology |
|
| |
|
Symposium on New Discoveries and Achievements of Cancer Research |
|
| |
|
Symposium on Latest Advances in Cardiovascular Research and Therapeutics Development |
|
| |
|
Symposium on Innovation on CNS Research and Therapeutics Development |
|
| |
|
Symposium on Updates on Diabetes Research and Therapy |
|
|
| |
|
|
• Online Registration is Open
October 1st, 2019 |
|
• Call for speakers!
September 1st, 2019 |
|
• Welcome to the website of WCDI-2021
August 15th, 2019 |
|
|
| |
|
|
• Abstract Submission Start Day
September 1st, 2019 |
|
• Earlybird Registration Start Day
October 1st, 2019 |
|
• Earlybird Registration Deadline
December 31st, 2019
|
|
• Abstract Submission Deadline
June 30th, 2022
|
|
• Acceptance Notification Deadline
July 20 th, 2022 |
|
|
|
|
|
|
| Postpone Notice |
|
World Congress on Drug Innovation (WCDI) is designed for inspiring international and interdisciplinary exchange at the forefront of drug research and to accelerate the cooperation for new drug research and development, and novel DDS technologies in the global market. The conference feature talks from Recent Advancements on Drug Discovery Science and Technology to Novel Drug Delivery Systems and Technology. During this special period of global pandemic, WCDI-2021 has to be postponed to next year. Instead, we provide online talk series for scientists, researchers, entrepreneurs, and decision makers from all over the world to debate on the latest scientific advances in the field of drug discovery & delivery that help to shape current and future challenges in drug research. We sincerely hope that you will take this opportunity to join us for academic exchange and business partnership. On behalf of the organizing committee, we highly appreciate your support and understanding.
The organizing committee of WCDI |
| |
|
|
|
|
|
| |
Welcome to attend World Congress on Drug Innovation (WCDI-2021) during August 12-14, 2021 in Shanghai, China. We cordially invite all the participants interested in sharing their knowledge and research in the arena of drug discovery and delivery.
WCDI-2021 provide a significant platform for inspiring international and interdisciplinary exchange at the forefront of drug research and to accelerate the cooperation for new drug research and development, and novel DDS technologies in the global market. The conference feature talks from Recent Advancements on Drug Discovery Science and Technology to Novel Drug Delivery Systems and Technology. The scientific program will feature plenary forum I for drug discovery, plenary forum II for drug delivery, 30+ breakout sessions, panel discussion, networking activities, poster showcase and exhibitions. Our endeavor is to provide a stimulating and thought provoking scientific program.
WCDI-2021 will bring together scientists, researchers, entrepreneurs, academicians, medical officers, and decision makers from all over the world to debate on the latest scientific advances in the field of drug discovery & delivery that help to shape current and future challenges in drug research.
Finally, we sincerely hope that you will take this opportunity to join us for academic exchange and business partnership. Look forward to meeting you in this great city of Shanghai, China. |
|
Honorary Chairman
|
 |
Chong-Su Cho, Fellow of Korean Academy of Science and Technology, Fellow of International Union of Societies for Biomaterials Science and Engineering;
Research Professor, Research Institute for Agriculture and Life Sciences, Seoul National University, South Korea
Learn More |
|
| |
|
Renowned Speakers |
|
Chong-Su Cho, Fellow of Korean Academy of Science and Technology, Fellow of International Union of Societies for Biomaterials Science and Engineering;
Research Professor, Research Institute for Agriculture and Life Sciences, Seoul National University, South Korea |
 |
Dr. Feng Qian, Professor and Vice Dean, School of Pharmaceutical Sciences, Tsinghua University, China |
| |
|
|
|
 |
Dr. C. I.Edvard SMITH, Professor, Karolinska Institutet, Sweden |
 |
Dr. Richard Soll, Senior Vice President, Research Service Division, WuXi AppTec, USA |
| |
|
|
|
Dang.png) |
Dr. Qun (Max) Dang, Corporate Vice President, CSPC PHARMA LTD, China |
 |
Dr. Jing Li, Senior Vice President, WuXi Biologics, China |
| |
|
|
|
 |
Dr. Tomasz Janecki, Professor, Director of the Institute of Organic Chemistry, Lodz University of Technology, Poland |
 |
Dr. Hong Ling, CSO&SVP, Leads Biolabs, China |
| |
|
|
|
 |
Dr. Marco Falasca, Professor, Head Metabolic Signaling Group, School of Pharmacy & Biomedical Sciences, Faculty of Health Sciences, Curtin University, Australia |
 |
Dr. Ketan Mehta, Founder and CEO, Tris Pharma Inc., USA |
| |
|
|
|
 |
Yueqing Gu, Professor, Biomedical Engineering; Dean, School of Engineering; Director, Molecular imaging and Biomedical Engineering
China Pharmaceutical University, China |
 |
Dr.Kiyoshi NOKIHARA,Professor, CEO & CSO, HiPep Laboratories, Japan |
| |
|
|
|
 |
Jun-Kyu Suh, M.D, Ph.D, Inha-Hanlym Distinguished Professor, National Research Center for Sexual Medicine, Dept. of Urology, Inha University School of Medicine, South Korea
|
 |
Insang Lee, CEO of Divine Lab Co Ltd., South Korea |
| |
|
|
|
 |
Kiminobu Sugaya, Professor and Head of Neuroscience, Chair of Multidisciplinary Neuroscience Alliance, College of Medicine, University of Central Florida, Orlando FL, USA |
 |
Urban Fagerholm, Associate Professor, CEO at PROSILICO, Huddinge, Sweden |
| |
|
|
|
 |
Vivek (Vic) Kadambi, Ph.D., Senior Vice President, Quantitative Pharmacology & Drug Safety, Blueprint Medicines, USA |
|
|
|
| |
|
| |
| |
| |
| |
|
